ChemoCentryx, Inc.: insider trades · United States · SEC (Form 4)

About ChemoCentryx, Inc.

ChemoCentryx, Inc. was a U.S.-based biopharmaceutical company historically listed on the NASDAQ under the ticker CCXI and headquartered in Mountain View, California, United States. From an equity-research perspective, it fit the profile of a clinical-stage biotech company with a focus on orally administered therapies for autoimmune diseases, inflammatory disorders, and selected cancers. The company was founded in the 1990s and built its strategy around the discovery and development of small-molecule drugs that target specific immune pathways, especially complement biology and leukocyte trafficking. Its lead asset was avacopan, marketed as TAVNEOS, an oral therapy used in anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis). This product became the key value driver for the business and the main reason ChemoCentryx attracted attention from specialist biotech investors. Moving from late-stage clinical development into commercialization, TAVNEOS gave the company a clearer pathway to revenue, while also highlighting the attractiveness of differentiated oral medicines in severe immune-mediated diseases. In addition to avacopan, ChemoCentryx had broader research programs in immunology, inflammation, and oncology, but its competitive identity was primarily built around targeted mechanism-of-action innovation rather than a broad commercial portfolio. Competitively, ChemoCentryx operated in a niche biotech segment where value creation depends heavily on clinical data, regulatory milestones, reimbursement dynamics, and launch execution. Its strategic appeal came from addressing serious and relatively rare conditions where an effective oral treatment can potentially command premium pricing and offer a meaningful convenience advantage versus infused or hospital-based alternatives. For investors, the company represented the classic high-risk/high-reward biotechnology model: a concentrated pipeline, high sensitivity to trial outcomes, and meaningful upside if a lead asset gains adoption. A critical recent development is that ChemoCentryx is no longer an independent publicly traded company. Amgen announced and then completed the acquisition of ChemoCentryx in 2022, meaning CCXI ceased to function as a standalone listed equity after that transaction. As a result, any historical analysis of ChemoCentryx should be viewed through the lens of an acquired asset rather than an ongoing public company. The company’s operating footprint was primarily California-based, with commercial relevance centered on the United States and other highly regulated pharmaceutical markets.